SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Clin. transl. oncol. (Print)
; 24(4): 703-711, abril 2022. ilus
Article
in English
| IBECS
| ID: ibc-203774
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the bloodbrain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Brain Neoplasms
/
Central Nervous System
/
Central Nervous System Neoplasms
/
Cerebrum
/
Melanoma
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article
Institution/Affiliation country:
Complexo Hospitalario Universitario A Coruña (CHUAC)/Spain
/
Consorcio Hospital General Universitario de Valencia/Spain
/
Hospital Clínic/Spain
/
Hospital Universitari Dr. Josep Trueta/Spain
/
Hospital Universitari i Politècnic la Fe/Spain
/
Hospital Universitario Puerta de Hierro Majadahonda/Spain
/
Hospital Universitario/Spain
/
Hospital del Mar/Spain
/
Institut Català dOncologia LHospitalet/Spain